Dr. Thy Huynh
Dermatology (Dermatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Alabama School of Medicine (2014)
- Years since graduation
- 12
- In the NPI registry since
- 2017
- Medicare patients seen, 2024
- 47
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Medical school: University of Alabama School of Medicine
- 2017Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
MS license 28771 -
Pediatric Dermatology Physician
MS license 28771 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Mississippi Med Center Jackson, MS
Medical groups
- State of Mississippi - University of Mississippi Medical Center (965 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 47
- Services billed
- 226
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 119 | 17 |
| Established patient office or other outpatient visit, 30-39 minutes | 29 | 22 |
| Destruction of precancer skin growth, 1 growth | 25 | 18 |
| Destruction of skin growth, 1-14 growths | 17 | 11 |
| Established patient office or other outpatient visit, 20-29 minutes | 13 | 12 |
| New patient office or other outpatient visit, 45-59 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ketoconazole Other prescribers in Jackson, MS | 39 |
| Ciclopirox (ciclopirox olamine) | 33 |
| Triamcinolone Acetonide Other prescribers in Jackson, MS | 30 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Jackson, MS | 25 |
| Mupirocin Other prescribers in Jackson, MS | 17 |
| Clindamycin Phosphate Other prescribers in Jackson, MS | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 57 payments worth $20,077 in total to this clinician.
| Incyte Corporation | $9,007 |
|---|---|
| Genzyme Corporation | $3,881 |
| Arcutis Biotherapeutics, Inc. | $2,754 |
| Botanix Sb Inc | $2,200 |
| Novartis Pharmaceuticals Corporation | $1,549 |
| Janssen Biotech, Inc. | $172 |
| Organon LLC | $160 |
| Galderma Laboratories, L.P. | $109 |
| Consulting Fee | $12,642 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $3,472 |
| Food and Beverage | $2,014 |
| Travel and Lodging | $1,948 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation Aug 8, 2025 | Consulting Fee OPZELURA · Dermatology | $3,900 |
| Incyte Corporation Aug 8, 2025 | Consulting Fee OPZELURA · Dermatology | $3,600 |
| Genzyme Corporation Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,472 |
| Arcutis Biotherapeutics, Inc. Aug 18, 2025 | Consulting Fee Zoryve · Dermatology | $2,250 |
| Botanix Sb Inc May 17, 2025 | Consulting Fee SOFDRA · DERMATOLOGY | $2,200 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $742 |
| Incyte Corporation Jun 25, 2025 | Consulting Fee OPZELURA · Dermatology | $692 |
| Incyte Corporation Jun 25, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Wilmington, DE | $358 |
| Arcutis Biotherapeutics, Inc. Sep 2, 2025 | Travel and Lodging Zoryve · Dermatology · travel to Seattle, WA | $348 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $299 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Nov 4, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,472 |
| Genzyme Corporation Nov 4, 2025 | Travel and Lodging DUPIXENT · Immunology · travel to Jackson, MS | $15.96 |
| Arcutis Biotherapeutics, Inc. Sep 2, 2025 | Travel and Lodging Zoryve · Dermatology · travel to Seattle, WA | $348 |
| Arcutis Biotherapeutics, Inc. Aug 18, 2025 | Consulting Fee Zoryve · Dermatology | $2,250 |
| Incyte Corporation Aug 8, 2025 | Consulting Fee OPZELURA · Dermatology | $3,900 |
| Incyte Corporation Aug 8, 2025 | Consulting Fee OPZELURA · Dermatology | $3,600 |
| Incyte Corporation Jun 26, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Philadelphia, PA | $120 |
| Incyte Corporation Jun 25, 2025 | Consulting Fee OPZELURA · Dermatology | $692 |
| Incyte Corporation Jun 25, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Wilmington, DE | $358 |
| Incyte Corporation Jun 25, 2025 | Travel and Lodging OPZELURA · Dermatology · travel to Jackson, MS | $34.88 |
| Botanix Sb Inc May 17, 2025 | Consulting Fee SOFDRA · DERMATOLOGY | $2,200 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $742 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Travel and Lodging travel to Orlando, FL · in-kind | $299 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Travel and Lodging travel to Orlando, FL | $30.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $66,955 in research payments for these studies, mostly to the institutions running them.
- 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-lab…
Novartis Pharmaceuticals Corporation - A Phase 2/3, Randomized, Double-Blinded, Placebo Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Argenx US, Inc. - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
Sanofi US Services Inc. · Completed · NCT06181435
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.